[go: up one dir, main page]

NO20054224L - Nye 2-pyridinkarboksamidderivater - Google Patents

Nye 2-pyridinkarboksamidderivater

Info

Publication number
NO20054224L
NO20054224L NO20054224A NO20054224A NO20054224L NO 20054224 L NO20054224 L NO 20054224L NO 20054224 A NO20054224 A NO 20054224A NO 20054224 A NO20054224 A NO 20054224A NO 20054224 L NO20054224 L NO 20054224L
Authority
NO
Norway
Prior art keywords
general formula
new
sulfur
oxygen
ring
Prior art date
Application number
NO20054224A
Other languages
English (en)
Other versions
NO20054224D0 (no
Inventor
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Teruyuki Nishimura
Jun-Ichi Eiki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20054224D0 publication Critical patent/NO20054224D0/no
Publication of NO20054224L publication Critical patent/NO20054224L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelse representert ved den generelle formel (I) eller farmasøytisk akseptable salter derav, som har glukokinaseaktiverende effekt og er anvendbare som sukkersykemedisiner: hvor X1 er nitrogen, svovel, oksygen eller lignende; R1 er 6-10-leddet aryl, 5-7-leddet heteroaryl eller lignende; D er oksygen eller svovel; R2 og R3 er uavhengig av hverandre hydrogen, lavere alkyl eller lignende; ringen A med den generelle formel (II): er eventuelt substituert 5-7-leddet heteroaryl eller lignende; og ringen B med den generelle formel (III): er en mono- eller bisyklisk heteroarylgruppe.
NO20054224A 2003-02-13 2005-09-12 Nye 2-pyridinkarboksamidderivater NO20054224L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22
PCT/JP2004/001568 WO2004081001A1 (ja) 2003-02-13 2004-02-13 新規2-ピリジンカルボキサミド誘導体

Publications (2)

Publication Number Publication Date
NO20054224D0 NO20054224D0 (no) 2005-09-12
NO20054224L true NO20054224L (no) 2005-11-10

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054224A NO20054224L (no) 2003-02-13 2005-09-12 Nye 2-pyridinkarboksamidderivater

Country Status (20)

Country Link
US (3) US7629362B2 (no)
EP (1) EP1598349B1 (no)
JP (1) JP4400563B2 (no)
KR (1) KR20050101208A (no)
AR (1) AR045414A1 (no)
AT (1) ATE517887T1 (no)
AU (2) AU2004220234C1 (no)
BR (1) BRPI0407283A (no)
CA (1) CA2515841C (no)
EC (1) ECSP056016A (no)
IL (1) IL169905A0 (no)
MA (1) MA27626A1 (no)
MX (1) MXPA05008619A (no)
NO (1) NO20054224L (no)
NZ (1) NZ540791A (no)
PE (1) PE20050194A1 (no)
TW (1) TWI336329B (no)
UA (1) UA82867C2 (no)
WO (1) WO2004081001A1 (no)
ZA (1) ZA200504852B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7812167B2 (en) 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ1ライアノジン受容体に基づく方法
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20070149547A1 (en) * 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
EP1806337A4 (en) 2004-10-08 2009-11-25 Banyu Pharma Co Ltd METHOD FOR THE SYNTHESIS OF A THIOETHER COMPOUND
WO2006049304A1 (ja) 2004-11-02 2006-05-11 Banyu Pharmaceutical Co., Ltd アリールオキシ置換ベンズイミダゾール誘導体
PE20061099A1 (es) * 2005-02-25 2006-12-05 Takeda Pharmaceutical Compuestos de piridil acido acetico como inhibidores de peptidasa
AU2006222289A1 (en) 2005-03-04 2006-09-14 F. Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mG1uR5 antagonists
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7408069B2 (en) 2005-08-05 2008-08-05 Bristol-Myers Squibb Company Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
EP1934216B1 (en) 2005-10-05 2010-11-24 F. Hoffmann-La Roche AG Naphthyridin derivatives
AU2006309173B2 (en) * 2005-11-01 2011-08-18 Array Biopharma Inc. Glucokinase activators
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
MY148985A (en) * 2006-03-24 2013-06-28 Array Biopharma Inc 2-aminopyridine analogs as glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
MX2009000688A (es) * 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
US7700593B2 (en) * 2006-10-11 2010-04-20 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
JP5207981B2 (ja) 2007-01-10 2013-06-12 田辺三菱製薬株式会社 ヒドラゾン誘導体
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2173745A2 (en) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
US20100190980A1 (en) * 2007-06-21 2010-07-29 Taisho Pharmaceutical Co., Ltd Pyrazinamide compound
EP2020232A1 (en) * 2007-08-03 2009-02-04 Zeltia, S.A. N-(1-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases
AU2008305294B2 (en) * 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2011502982A (ja) * 2007-11-06 2011-01-27 アストラゼネカ・アクチエボラーグ 好中球エラスターゼの阻害剤としてのある種の2−ピラジノン誘導体およびその使用
WO2009063821A1 (ja) 2007-11-12 2009-05-22 Banyu Pharmaceutical Co., Ltd. ヘテロアリールオキシキナゾリン誘導体
JPWO2009081782A1 (ja) 2007-12-25 2011-05-06 萬有製薬株式会社 N−ピラゾール−2−ピリジンカルボキサミド誘導体
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
US20110009437A1 (en) * 2008-02-27 2011-01-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Carboxamide-heteroaryl derivatives for the treatment of diabetes
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
AU2009280579A1 (en) 2008-08-15 2010-02-18 Banyu Pharmaceutical Co.,Ltd. Acetyl pyrrolidinyl indole derivative
CA2734981A1 (en) * 2008-08-29 2010-03-04 Banyu Pharmaceutical Co., Ltd. Oxotetrahydrofuran-2-yl-benzimidazole derivative
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN102388038B (zh) * 2009-03-11 2014-04-23 辉瑞大药厂 用作葡糖激酶活化剂的苯并呋喃基衍生物
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JP5750050B2 (ja) 2009-12-04 2015-07-15 大正製薬株式会社 2−ピリドン化合物
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
MX2014012465A (es) 2012-04-16 2015-01-12 Kaneq Pharma Inc Derivados de fosfonato aromaticos fusionados como precursores de inhibidores de tirosina fosfatasa de proteina 1b.
EP2931718B1 (en) * 2012-12-17 2019-01-16 Merck Sharp & Dohme Corp. Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20240067657A1 (en) * 2020-12-29 2024-02-29 Merck Sharp & Dohme Llc Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) * 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (no) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
SE519859C2 (sv) 2001-08-17 2003-04-15 Novacast Ab Anordning för behandling av järnlegeringar i ett kärl
AU2002952839A0 (en) * 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
UA82867C2 (en) 2003-02-13 2008-05-26 Banyu Pharma Co Ltd 2-pyridinecarboxamide derivatives
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
ES2322709T3 (es) 2004-02-18 2009-06-25 Astrazeneca Ab Derivados de benzamida y su uso como agentes activadores de la glucocinasa.
EP1718625A1 (en) 2004-02-18 2006-11-08 AstraZeneca AB Compounds
EP1806337A4 (en) * 2004-10-08 2009-11-25 Banyu Pharma Co Ltd METHOD FOR THE SYNTHESIS OF A THIOETHER COMPOUND
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
US20130085156A1 (en) 2013-04-04
US8344003B2 (en) 2013-01-01
NO20054224D0 (no) 2005-09-12
AU2004220234C1 (en) 2013-01-17
JPWO2004081001A1 (ja) 2006-06-08
BRPI0407283A (pt) 2006-01-31
EP1598349A1 (en) 2005-11-23
US7629362B2 (en) 2009-12-08
EP1598349B1 (en) 2011-07-27
CA2515841A1 (en) 2004-09-23
AU2010200004B2 (en) 2012-07-19
WO2004081001A1 (ja) 2004-09-23
AU2004220234B2 (en) 2009-11-26
JP4400563B2 (ja) 2010-01-20
US8765789B2 (en) 2014-07-01
AR045414A1 (es) 2005-10-26
US20100041660A1 (en) 2010-02-18
TW200510381A (en) 2005-03-16
EP1598349A4 (en) 2008-12-31
KR20050101208A (ko) 2005-10-20
ECSP056016A (es) 2006-01-27
PE20050194A1 (es) 2005-04-23
IL169905A0 (en) 2007-07-04
MXPA05008619A (es) 2005-11-04
HK1088602A1 (zh) 2006-11-10
AU2004220234A1 (en) 2004-09-23
TWI336329B (en) 2011-01-21
UA82867C2 (en) 2008-05-26
US20060258701A1 (en) 2006-11-16
ZA200504852B (en) 2006-05-31
NZ540791A (en) 2009-09-25
AU2010200004A1 (en) 2010-01-28
MA27626A1 (fr) 2005-11-01
ATE517887T1 (de) 2011-08-15
CA2515841C (en) 2010-06-01

Similar Documents

Publication Publication Date Title
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
NO20061076L (no) (Tio)karbamoylsykloheksanderivater som D3/D2 -reseptorantagonister
NO20052038L (no) Ny adeninforbindelse og anvendelse derav
NO20054425L (no) Heteroarylkarbamoylbenzenderivater
NO20053614L (no) Nye pyridazin-3(2H)-on-derivater
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
EA200601235A1 (ru) Производные тиазола
ATE443990T1 (de) 3-heteroarylsubstituierte 5-methyloxymethyl- isoxazoline als herbizide
ES2193839A1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2005028445A3 (en) Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20052887L (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
EP1695961A4 (en) UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
NO20062370L (no) Amidderivater
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
TW200745034A (en) New compounds
NO20055977L (no) Nye benzimidazolderivater
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
NO20063132L (no) Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
NO20071754L (no) Biotinylerte heksadekasakkarider, fremstilling og anvendelse derav
EA200001101A1 (ru) НОВЫЕ ДИГИДРОФУРО[3,4-b]ХИНОЛИН-1-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application